US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Weight Loss Drugs

1,257.83

+13.801.11%

Number of Gainers:6

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,263.83

Open:1,245.45

Low:1,245.45

Close:1,244.03

Loading ...

Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals

Pfizer’s Braftovi® Combination Regimen Cuts the Risk of Death in Half for Patients With Braf V600e-Mutant Metastatic Colorectal Cancer

THOMSON REUTERS

Pfizer Inc - Phase 3 Breakwater Trial Shows 51% Risk Reduction in Death Compared to Standard-of-Care Treatment

THOMSON REUTERS

2 Top Stocks to Buy With Less Than $100

Pfizer: Breakwater Survival Data Being Discussed With U.S. FDA to Support Potential Conversion to Full Approval in 2025

THOMSON REUTERS

Pfizer: Braftovi Combination Regimen Met Trial’s Dual Primary Endpoint of Progression-Free Survival

THOMSON REUTERS

2 Beaten-Down Stocks to Buy on the Dip

Pantera Lithium Secures Favorable 2.5% Royalty for Smackover Project

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Health Rounds: Amgen's blood platelet booster helps patients who need chemotherapy

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created

Is Amgen Stock a Buy?

Option traders moderately bearish in Pfizer with shares down 1.29%

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading

MT Newswires Live

ADVISORY-Alert on Pfizer from law firm's press release withdrawn

Pfizer Faces Multidistrict Litigation in the US Over Depo-Provera's Alleged Link to Brain Tumors

Possible Bearish Signals With Amgen Insiders Disposing Stock

Simply Wall St.

Advisory: an Alert Tagged to Pfizer From a Law Firm Release Is Being Withdrawn

THOMSON REUTERS

Hearing Against Pfizer Set for 30 May in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio

THOMSON REUTERS

Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4599/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1257.8302,"timestamp":1749239999999,"preClose":1244.0306,"halted":0,"volume":51513461,"delay":0,"changeRate":0.011093,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":13.799561,"latestTime":"06-06 16:00:00 EDT","open":1245.4493,"high":1263.8325,"low":1245.4493,"amount":3711906755.507839,"amplitude":0.014777,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.634273,"peRate":32.113496,"turnoverRate":0.004869,"increases":6,"decrements":1,"flats":0,"marketCap":1354591922304,"floatMarketCap":1258679594368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1263.8325,"amplitude":0.014777,"preClose":1244.0306,"low":1245.4493,"pbRate":"9.634273","latestPrice":1257.8302,"volume":51513461,"delay":0,"open":1245.4493,"prevYearClose":1305.0607,"prevWeekClose":1216.6,"prevMonthClose":1216.6,"prevQuarterClose":1314.3724,"fiveDayClose":1216.6,"twentyDayClose":1196.4727,"sixtyDayClose":1333.0085,"secType":"PLATE","market":"US","turnoverRate":0.004869,"peRate":32.113496,"marketCap":1354591922304,"floatMarketCap":1258679594368,"timestamp":1749239999999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":6,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2539722463","title":"Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals","url":"https://stock-news.laohu8.com/highlight/detail?id=2539722463","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539722463?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:01","pubTimestamp":1748606490,"startTime":"0","endTime":"0","summary":"Pfizer's BRAFTOVI Combo Reduces Death Risk by Half in BRAF V600E-Mutant Metastatic Colorectal Cancer, BREAKWATER Trial Reveals. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire  on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"82b453f3c55aa623ccd5280b27914b5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL1j4dkG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU0985481810.HKD","LU0289739699.SGD","IE000M9KFDE8.USD","BK4533","BK4581","LU0058720904.USD","BK4588","SG9999002232.USD","SG9999013999.USD","LU1066051498.USD","IE0002270589.USD","BK4550","IE00B19Z3581.USD","LU0122379950.USD","BK4534","BK4592","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1057294990.SGD","SG9999001176.SGD","SG9999001176.USD","BK4599","LU1883839398.USD","BK4568","LU0306807586.USD","LU0868494617.USD","BK4007","LU0456855351.SGD","LU0306806265.USD","LU0321505439.SGD","LU0234572021.USD","LU1023059063.AUD","SG9999011175.SGD","BK4585","SG9999002224.SGD","LU0170899867.USD","LU0321505868.SGD","LU1894683348.USD","LU1894683264.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","SG9999003800.SGD","SGXZ57979304.SGD","LU0225771236.USD","LU1066053197.SGD"],"gpt_icon":1},{"id":"2539248192","title":"Pfizer’s Braftovi® Combination Regimen Cuts the Risk of Death in Half for Patients With Braf V600e-Mutant Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539248192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539248192?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"82b453f3c55aa623ccd5280b27914b5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5DB8B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","IE00BBT3K403.USD","SG9999001176.SGD","SG9999003800.SGD","LU0306806265.USD","BK4592","BK4581","PFE","SG9999013999.USD","SGXZ57979304.SGD","BK4568","LU0321505868.SGD","SG9999001176.USD","SG9999002232.USD","IE00B19Z3581.USD","LU0234572021.USD","LU1894683264.USD","LU1894683348.USD","BK4007","LU0306807586.USD","LU1057294990.SGD","LU1066053197.SGD","LU0058720904.USD","LU0321505439.SGD","BK4533","SG9999002224.SGD","LU1023059063.AUD","BK4585","LU0456855351.SGD","IE000M9KFDE8.USD","BK4550","BK4599","LU0985481810.HKD","IE0002270589.USD","LU0868494617.USD","SG9999011175.SGD","LU0225771236.USD","LU0289739699.SGD","LU1883839398.USD","LU0225284248.USD","LU0122379950.USD","BK4588","IE00BLSP4239.USD","LU0170899867.USD"],"gpt_icon":0},{"id":"2539224641","title":"Pfizer Inc - Phase 3 Breakwater Trial Shows 51% Risk Reduction in Death Compared to Standard-of-Care Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224641","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224641?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nTUA5DB8B7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","LU0170899867.USD","SG9999011175.SGD","LU1894683264.USD","LU0225771236.USD","LU0122379950.USD","LU0321505868.SGD","LU0321505439.SGD","SG9999002232.USD","LU1894683348.USD","BK4581","LU1883839398.USD","LU0985481810.HKD","LU0306806265.USD","BK4588","LU0456855351.SGD","LU1057294990.SGD","SG9999001176.SGD","SGXZ57979304.SGD","LU0868494617.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","BK4568","BK4585","LU1066051498.USD","BK4592","IE00BBT3K403.USD","BK4599","SG9999013999.USD","BK4550","BK4533","LU1066053197.SGD","LU0058720904.USD","PFE","SG9999002224.SGD","LU0225284248.USD","SG9999001176.USD","BK4534","IE00BLSP4239.USD","SG9999003800.SGD","LU0289739699.SGD","LU0306807586.USD","LU0234572021.USD","IE0002270589.USD","BK4007","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2539247832","title":"2 Top Stocks to Buy With Less Than $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2539247832","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539247832?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606400,"startTime":"0","endTime":"0","summary":"Novo Nordisk should perform well thanks to new leadership and a strong underlying business.Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/30/2-top-stocks-to-buy-with-less-than-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1093756168.USD","BK4599","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","NVO","BK4532","BK4588"],"gpt_icon":0},{"id":"2539224842","title":"Pfizer: Breakwater Survival Data Being Discussed With U.S. FDA to Support Potential Conversion to Full Approval in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224842?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nP8N3NL004:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0306806265.USD","LU1894683264.USD","BK4568","BK4599","BK4534","LU0321505439.SGD","LU0321505868.SGD","LU0289739699.SGD","SG9999002232.USD","LU0985481810.HKD","SG9999001176.USD","BK4533","LU0225771236.USD","BK4007","IE0002270589.USD","LU0225284248.USD","SG9999011175.SGD","LU0058720904.USD","SGXZ57979304.SGD","SG9999002224.SGD","SG9999001176.SGD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0456855351.SGD","LU0170899867.USD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4588","BK4585","LU1066053197.SGD","LU0234572021.USD","LU0306807586.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU1894683348.USD","BK4592","BK4550","LU1066051498.USD","IE00B19Z3581.USD","PFE","LU0868494617.USD","LU1057294990.SGD","LU0122379950.USD","SG9999013999.USD"],"gpt_icon":0},{"id":"2539224815","title":"Pfizer: Braftovi Combination Regimen Met Trial’s Dual Primary Endpoint of Progression-Free Survival","url":"https://stock-news.laohu8.com/highlight/detail?id=2539224815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539224815?lang=en_us&edition=fundamental","pubTime":"2025-05-30 20:00","pubTimestamp":1748606400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"82b453f3c55aa623ccd5280b27914b5b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nP8N3NL004:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","LU1894683348.USD","IE00BBT3K403.USD","BK4550","LU0289739699.SGD","LU0321505868.SGD","LU0234572021.USD","LU0456855351.SGD","LU0306806265.USD","LU0225771236.USD","IE000M9KFDE8.USD","BK4533","SG9999002232.USD","BK4007","LU0985481810.HKD","BK4599","LU1066053197.SGD","LU0058720904.USD","LU1066051498.USD","BK4592","LU1883839398.USD","LU0306807586.USD","SG9999011175.SGD","SG9999013999.USD","IE0002270589.USD","SG9999003800.SGD","BK4568","LU0225284248.USD","LU0170899867.USD","SG9999002224.SGD","LU1023059063.AUD","IE00BLSP4452.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","SG9999001176.USD","LU0122379950.USD","BK4585","BK4534","BK4581","LU1057294990.SGD","IE00B19Z3581.USD","PFE","LU1894683264.USD","IE00B19Z3B42.SGD","BK4588","SG9999001176.SGD","LU0868494617.USD"],"gpt_icon":0},{"id":"2539299822","title":"2 Beaten-Down Stocks to Buy on the Dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2539299822","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539299822?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:00","pubTimestamp":1748602800,"startTime":"0","endTime":"0","summary":"Novo Nordisk has strengths, including a deep pipeline, that should help it overcome recent obstacles.Cava Group's results are excellent, and in the long run the restaurant chain still has strong potential.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/30/2-beaten-down-stocks-to-buy-on-the-dip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BKVL7J92.USD","BK4588","BK4532","LU1093756168.USD","BK4007","NVO","BK4585","BK4599","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD"],"gpt_icon":1},{"id":"2539291276","title":"Pantera Lithium Secures Favorable 2.5% Royalty for Smackover Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2539291276","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539291276?lang=en_us&edition=fundamental","pubTime":"2025-05-30 06:49","pubTimestamp":1748558963,"startTime":"0","endTime":"0","summary":"Pantera Minerals Ltd. ( ($AU:PFE) ) has issued an announcement. Pantera Lithium Ltd has welcomed the Arkansas Oil & Gas Commission’s decision to ap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pantera-lithium-secures-favorable-2-5-royalty-for-smackover-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pantera-lithium-secures-favorable-2-5-royalty-for-smackover-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","BK4533","LU1023059063.AUD","SG9999001176.SGD","SG9999011175.SGD","PFE","LU0058720904.USD","BK4581","IE000M9KFDE8.USD","LU0289739699.SGD","LU0225284248.USD","LU0456855351.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","BK4592","IE00B19Z3B42.SGD","LU1066051498.USD","LU1066053197.SGD","BK4599","BK4568","LU1894683348.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4550","SG9999002232.USD","SG9999013999.USD","IE0002270589.USD","BK4588","LU0170899867.USD","BK4007","SG9999003800.SGD","LU1057294990.SGD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002224.SGD","LU0321505868.SGD","BK4585","LU1894683264.USD","SG9999001176.USD","BK4534","LU0225771236.USD","LU0306807586.USD","IE00B19Z3581.USD","LU0321505439.SGD","LU0234572021.USD","LU0306806265.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2539483229","title":"Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2539483229","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539483229?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:05","pubTimestamp":1748549100,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, May  29, 2025  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/29/3090713/0/en/Structure-Therapeutics-to-Participate-in-Multiple-Upcoming-Healthcare-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4137","BK4007","LENZ","GPCR","BK4539","BK4599","HCSG"],"gpt_icon":0},{"id":"2539260779","title":"Health Rounds: Amgen's blood platelet booster helps patients who need chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2539260779","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539260779?lang=en_us&edition=fundamental","pubTime":"2025-05-30 02:17","pubTimestamp":1748542627,"startTime":"0","endTime":"0","summary":"Health Rounds: Amgen's blood platelet booster helps patients who need chemotherapyHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy Lapid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nL2N3RZ0SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","LU1003077747.HKD","BK4599","LU1019634622.SGD","LU1301847155.USD","BK0239","LU2089283258.USD","LU0203347892.USD","SG9999001176.SGD","LU2091194634.USD","LU0029864427.USD","688235","LU0211326755.USD","LU0757432116.USD","LU0882574055.USD","LU1064927863.SGD","LU0640478417.SGD","AMGN","LU0545039389.USD","LU0345777147.USD","LU1267930573.SGD","BK4534","LU0661504455.SGD","LU0784384876.USD","LU1078025761.USD","SG9999001440.SGD","LU1051770623.HKD","LU1487256676.USD","LU2324357040.USD","LU0738911758.USD","IE00BFTCPJ56.SGD","LU0077335932.USD","LU0211327993.USD","LU0122379950.USD","LU0114720955.EUR","LU0211328371.USD","LU0557290698.USD","IE0009355771.USD","03165","LU0203345920.USD","LU0976567544.SGD","LU1023059063.AUD","LU1153584641.USD","LU0889565916.HKD","LU0784383803.USD","LU1291159041.SGD","LU0345777659.USD","LU0957799991.USD","LU2468319806.SGD","LU0047473722.EUR"],"gpt_icon":0},{"id":"2539831752","title":"How Ozempic's Maker Lost Its Grip on the Obesity Market It Created","url":"https://stock-news.laohu8.com/highlight/detail?id=2539831752","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539831752?lang=en_us&edition=fundamental","pubTime":"2025-05-29 17:52","pubTimestamp":1748512340,"startTime":"0","endTime":"0","summary":"In 2023, Novo Nordisk was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy.Today, the Danish company has lost its grip on the anti-obesity market it carved out.The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly -- initially in the rearview mirror -- has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground.Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jrgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 5","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a73185ae582feb1fc76eef071b4b5bbf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"How Ozempic's Maker Lost Its Grip on the Obesity Market It Created","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU0203201768.USD","LU2552382215.SGD","BK4516","LU2491049909.HKD","LU0122379950.USD","SGXZ81514606.USD","LU2106854487.HKD","LU2237443549.SGD","LU2471134879.HKD","LU0320765059.SGD","LU0640476718.USD","LU1093756325.SGD","SG9999018865.SGD","BK4581","LU2324357040.USD","LU0466842654.USD","LU0058720904.USD","LU0471298777.SGD","LU1720051017.SGD","SG9999014906.USD","MKR.USD.CC","LU1551013342.USD","BK4585","LU2063271972.USD","LU0238689110.USD","BK4599","IE00B1BXHZ80.USD","NVO","LU0198837287.USD","IE00BJLML261.HKD","LU2746668461.USD","LU0385154629.USD","LU0471298694.HKD","BK4533","LU1868837136.USD","LU2471134796.USD","SG9999014914.USD","LU2264538146.SGD","IE00BK4W5M84.HKD","LU0109394709.USD","LU0456855351.SGD","LU1623119135.USD","LU2361044949.HKD","MKR.USD.HKCC","LU0417517546.SGD","LU0109391861.USD","BK4532","SG9999014898.SGD"],"gpt_icon":0},{"id":"2539376022","title":"Is Amgen Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2539376022","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539376022?lang=en_us&edition=fundamental","pubTime":"2025-05-29 16:45","pubTimestamp":1748508300,"startTime":"0","endTime":"0","summary":"Amgen shares trade at just 13 times forward earnings estimates, a steep discount to the S&P 500.The biotech pioneer posted strong Q1 2025 results with 14 drugs delivering double-digit sales growth.The dividend yields an attractive 3.5% and shares have outperformed the S&P 500 with a 7% gain year to date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/29/is-amgen-stock-a-buy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4559","LU0868494617.USD","UPRO",".SPX","BK4599","LU0122379950.USD","IE00B2B36J28.USD","LU2089984988.USD","LU2112291526.USD","LU2242646821.SGD","LU0889565916.HKD","LU2242652126.USD","BK4581","SPXU","AMGN","SDS","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0289739699.SGD","SH","LU0109394709.USD","MESmain","OEF","BK4550","LU1983299246.USD","SPY","BK4585","LU1571399168.USD","BK4533","IVV","LU1023059063.AUD","BK4588","LU2468319806.SGD","BK4566","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4139","ESmain","OEX","LU1061106388.HKD","LU0320765992.SGD","SSO","VOO","LU1057294990.SGD","SG9999001440.SGD","BK4534","IE00BJT1NW94.SGD","LU0058720904.USD","BK4504","IE0009355771.USD"],"gpt_icon":0},{"id":"2539470063","title":"Option traders moderately bearish in Pfizer with shares down 1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2539470063","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539470063?lang=en_us&edition=fundamental","pubTime":"2025-05-29 00:10","pubTimestamp":1748448622,"startTime":"0","endTime":"0","summary":"Option traders moderately bearish in Pfizer (PFE), with shares down 30c near $23.30.Options volume roughly in line with average with 91k contracts ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-pfizer-with-shares-down-1-29-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/option-traders-moderately-bearish-in-pfizer-with-shares-down-1-29-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0122379950.USD","BK4533","LU1023059063.AUD","SG9999001176.SGD","SG9999011175.SGD","PFE","LU0058720904.USD","BK4581","IE000M9KFDE8.USD","LU0289739699.SGD","LU0225284248.USD","LU0456855351.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","BK4592","IE00B19Z3B42.SGD","LU1066051498.USD","LU1066053197.SGD","BK4599","BK4568","LU1894683348.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4550","SG9999002232.USD","SG9999013999.USD","IE0002270589.USD","BK4588","LU0170899867.USD","BK4007","SG9999003800.SGD","LU1057294990.SGD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002224.SGD","LU0321505868.SGD","BK4585","LU1894683264.USD","SG9999001176.USD","BK4534","LU0225771236.USD","LU0306807586.USD","IE00B19Z3581.USD","LU0321505439.SGD","LU0234572021.USD","LU0306806265.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2538720814","title":"European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2538720814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538720814?lang=en_us&edition=fundamental","pubTime":"2025-05-28 23:00","pubTimestamp":1748444448,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.93% to 1,450.69 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion  and furniture maker Natuzzi , which advanced 14% and 11% respectively. They were followed by biopharmaceutical company Genfit  and internet browser company Opera , which rose 1.9% and 1.7% respectively.The decliners from continental Europe were led by Spanish lender Banco Bilbao Vizcaya Argentaria  and pharmaceutical company Novo Nordisk , which fell 2.1% and 1.8% respectively. They were followed by Dutch financial services company ING  and petroleum refiner Equinor , which were down 1.5% and 1.3% respectively.From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics  and biopharmaceutical company Bicycle Therapeutics , which climbed 4.5% and 4.3% respectively. They were followed by biopharmaceutical companies Amarin  an","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EQNR","BK4208","AFG","NTZ","LU1093756168.USD","OPRA","BK4532","GNFT","NGG","BK7141","AUTL","BK4599","LU0154236417.USD","NVO","BK7505","BBVA","LU1093756325.SGD","BCYC","TRIB","BK4082","BK4201","BK4588","BK7104","BDRX","BK4023","IE00BKVL7J92.USD","AMRN","NCNA","NVO.AU","BK4117","BK4107","IE00BZ1G4Q59.USD","ADAP","BK4007","BK4095","BK4207","EVAX","ING.AU","BK4139","BK4585","ING"],"gpt_icon":1},{"id":"2538753064","title":"ADVISORY-Alert on Pfizer from law firm's press release withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2538753064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538753064?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:06","pubTimestamp":1748434009,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert on Pfizer from law firm's press release withdrawnAn alert on a court hearing against Pfizer PFE.N was inadvertently published from a law firm's press release and has been withdrawn. The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUAMRJWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4588","IE0002270589.USD","SG9999011175.SGD","LU1894683348.USD","SG9999001176.SGD","LU0321505439.SGD","LU0234572021.USD","LU0985481810.HKD","BK4534","BK4550","IE000M9KFDE8.USD","LU0225284248.USD","LU1066053197.SGD","SGXZ57979304.SGD","PFE","BK4585","LU0289739699.SGD","LU1057294990.SGD","SG9999002232.USD","BK4007","LU1066051498.USD","LU0225771236.USD","LU0456855351.SGD","LU0122379950.USD","BK4581","LU1894683264.USD","SG9999013999.USD","SG9999001176.USD","LU0306806265.USD","LU0058720904.USD","IE00B19Z3581.USD","BK4599","LU0868494617.USD","LU1883839398.USD","SG9999003800.SGD","LU0170899867.USD","SG9999002224.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","BK4533","LU0321505868.SGD","LU0306807586.USD","LU1023059063.AUD","IE00BLSP4452.SGD","IE00B19Z3B42.SGD","BK4592"],"gpt_icon":0},{"id":"2538447376","title":"Pfizer Faces Multidistrict Litigation in the US Over Depo-Provera's Alleged Link to Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2538447376","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538447376?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433644,"startTime":"0","endTime":"0","summary":"Pfizer Inc. is currently facing a multidistrict litigation in the United States involving approximately 400 lawsuits related to its contraceptive injection, Depo-Provera. The lawsuits allege that Pfizer failed to adequately warn women in the U.S. about the increased risk of developing brain tumors, specifically meningiomas, after prolonged use of the drug. This legal action comes in the wake of a study published in March 2024 by EPI-PHARE in the British Medical Journal, which found that women using Depo-Provera for over a year were 5.6 times more likely to develop intracranial meningiomas. Despite adding warning labels in Canada, the UK, and Europe, Pfizer has not issued similar warnings in the U.S. A Case Management Conference is scheduled for May 30 in Pensacola, Florida, as part of the proceedings. The litigation is being supported by the law firm Levin Papantonio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL1xn9JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU0985481810.HKD","IE00BLSP4452.SGD","LU0306806265.USD","SG9999003800.SGD","LU0170899867.USD","IE00B19Z3B42.SGD","LU0289739699.SGD","LU0456855351.SGD","LU0306807586.USD","SG9999001176.SGD","SG9999001176.USD","IE0002270589.USD","LU1023059063.AUD","LU0058720904.USD","BK4534","IE000M9KFDE8.USD","SG9999011175.SGD","BK4007","LU1894683348.USD","SGXZ57979304.SGD","LU1066051498.USD","LU1883839398.USD","LU0122379950.USD","LU0234572021.USD","BK4550","LU0321505439.SGD","BK4585","BK4533","LU1066053197.SGD","BK4568","BK4588","IE00BLSP4239.USD","LU1894683264.USD","BK4599","PFE","IE00B19Z3581.USD","SG9999013999.USD","IE00BBT3K403.USD","LU0225284248.USD","SG9999002232.USD","SG9999002224.SGD","LU1057294990.SGD","LU0321505868.SGD","BK4581","LU0225771236.USD","BK4592"],"gpt_icon":1},{"id":"2539075034","title":"Possible Bearish Signals With Amgen Insiders Disposing Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2539075034","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539075034?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433628,"startTime":"0","endTime":"0","summary":"Many Amgen Inc.  insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.An insider hasn't bought Amgen stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. But it is good to see that Amgen is growing earnings. While insiders do own a lot of shares in the company , our analysis of their trans","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/possible-bearish-signals-amgen-insiders-120028584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","BK4139","LU2089984988.USD","LU0109394709.USD","BK4599","LU0058720904.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","LU0289739699.SGD","LU1983299246.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4585","LU2468319806.SGD","BK4534","LU1571399168.USD","LU2112291526.USD","LU0320765992.SGD","AMGN","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4566","IE00B2B36J28.USD","IE0002141913.USD","SG9999001440.SGD","LU1057294990.SGD","BK4533","LU2242652126.USD","LU1023059063.AUD","BK4588","LU0122379950.USD","LU0868494617.USD"],"gpt_icon":0},{"id":"2538880475","title":"Advisory: an Alert Tagged to Pfizer From a Law Firm Release Is Being Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2538880475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538880475?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUAMRJWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999003800.SGD","LU0225284248.USD","SG9999011175.SGD","IE0002270589.USD","LU0985481810.HKD","SG9999001176.SGD","IE00BLSP4239.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4550","LU0058720904.USD","LU0122379950.USD","LU0306807586.USD","LU0225771236.USD","SG9999002232.USD","LU1883839398.USD","SG9999001176.USD","LU1023059063.AUD","IE00BLSP4452.SGD","LU0321505439.SGD","LU1066051498.USD","LU0234572021.USD","LU0289739699.SGD","SGXZ57979304.SGD","LU1894683348.USD","BK4585","LU0306806265.USD","IE00BBT3K403.USD","PFE","BK4533","BK4592","LU0321505868.SGD","BK4568","BK4534","BK4599","LU0456855351.SGD","BK4007","LU1894683264.USD","LU1057294990.SGD","IE000M9KFDE8.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU1066053197.SGD","LU0170899867.USD","BK4581","BK4588"],"gpt_icon":0},{"id":"2538473720","title":"Hearing Against Pfizer Set for 30 May in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin Papantonio","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473720?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:00","pubTimestamp":1748433601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nTUAMRJWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1023059063.AUD","LU1883839398.USD","LU0306807586.USD","SG9999003800.SGD","BK4533","LU0306806265.USD","BK4585","IE0002270589.USD","LU0289739699.SGD","LU1066051498.USD","LU1066053197.SGD","LU1894683264.USD","LU0868494617.USD","IE00BLSP4239.USD","PFE","IE00BLSP4452.SGD","SG9999002232.USD","BK4534","SG9999001176.SGD","BK4599","SG9999013999.USD","IE000M9KFDE8.USD","LU0985481810.HKD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0321505868.SGD","LU0234572021.USD","SG9999001176.USD","BK4581","LU0170899867.USD","LU0456855351.SGD","LU0122379950.USD","BK4568","LU0225771236.USD","IE00B19Z3581.USD","BK4550","BK4588","SGXZ57979304.SGD","LU0321505439.SGD","BK4007","LU1894683348.USD","IE00BBT3K403.USD","LU1057294990.SGD","BK4592","SG9999011175.SGD","LU0058720904.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2538742054","title":"Pfizer and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season","url":"https://stock-news.laohu8.com/highlight/detail?id=2538742054","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538742054?lang=en_us&edition=fundamental","pubTime":"2025-05-28 18:58","pubTimestamp":1748429892,"startTime":"0","endTime":"0","summary":"Pfizer Inc. and BioNTech SE have submitted a regulatory application to the European Medicines Agency  for the approval of their COVID-19 vaccine, COMIRNATY, targeting the LP.8.1 strain for the 2025-2026 season. This submission follows the EMA's Emergency Task Force recommendation to update the vaccine composition to address the LP.8.1 strain. The vaccine, developed using BioNTech's proprietary mRNA technology, is aimed at enhancing protection against COVID-19 for individuals 12 years and older. The regulatory review is ongoing, and the companies are awaiting approval to proceed with distribution for the upcoming season.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL68xskw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0456855351.SGD","IE0002270589.USD","LU1894683348.USD","BNTX","BK4551","BK4535","LU1057294990.SGD","SGXZ57979304.SGD","BK4588","IE00B19Z3B42.SGD","SG9999013999.USD","BK4548","BK4550","LU0289739699.SGD","LU0234572021.USD","LU0321505439.SGD","PFE","SG9999001176.USD","BK4139","BK4534","SG9999003800.SGD","LU0306807586.USD","SG9999002232.USD","IE000M9KFDE8.USD","BK4581","IE00BLSP4239.USD","LU0225284248.USD","BK4599","BK4007","LU1023059063.AUD","LU0122379950.USD","LU0306806265.USD","LU0170899867.USD","IE00BLSP4452.SGD","LU0058720904.USD","BK4585","LU0321505868.SGD","BK4533","LU0985481810.HKD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","LU1883839398.USD","SG9999001176.SGD","SG9999002224.SGD","LU1894683264.USD","LU0868494617.USD","LU1066053197.SGD","BK4568"],"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}